Pharmanutra Stock price
Compare with Peer Group
AI Insights on Pharmanutra
Insights
Is Pharmanutra a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?
As a Free StocksGuide user, you can view scores for all 9,093 stocks worldwide.
Key metrics
Pharmanutra Stock Analysis
Analyst Opinions
7 Analysts have issued a Pharmanutra forecast:
Analyst Opinions
7 Analysts have issued a Pharmanutra forecast:
Pharmanutra Events
Upcoming Event
Don't miss a Thing! We will send you all news about Pharmanutra directly to your mailbox free of charge.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Company Profile
Pharmanutra SpA develops nutraceutical products and medical devices. The company is headquartered in Pisa, Pisa. The company went IPO on 2017-07-18. The firm develops nutraceutical products and medical devices. The company focuses on studying and producing formulations that are backed up in scientific research. The company is able to cover all stages of the development of a product, from its design, formulation and registration to its marketing, distribution and training of its commercial representatives. The firm offers Gestalys DHA, a nutritional supplement; Cetilar, a massage coadiuvant, improves and brings relief to joints affected by osteoarthritis; Cetilar patch, a transdermic patch containing a concentrated formulation of cetylated fatty acids (CFA) esters; SiderAL Forte; CardioSiderAL; SiderAL Folico; SiderAL; Bonecal and Novomega, among others.
| Head office | Italy |
| Employees | 128 |
| Website | www.pharmanutra.it |


